Skip to content

Accuracy of 68Ga-Pentixafor PET/CT for Subtypting Diagnosis in Patients With Primary Aldosteronism Concurrent With Autonomous Cortisol Secretion

Accuracy of 68Ga-Pentixafor PET/CT for Subtypting Diagnosis in Patients With Primary Aldosteronism Concurrent With Autonomous Cortisol Secretion

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06635993
Acronym
ABOARD
Enrollment
97
Registered
2024-10-10
Start date
2024-08-12
Completion date
2027-08-12
Last updated
2024-10-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary Aldosteronism Concurrent With Autonomous Cortisol Secretion

Keywords

primary aldosteronism, autonomous cortisol secretion, Adrenal venous sampling, 68Ga-Pentixafor PET/CT

Brief summary

To evaluate the accuracy of 68Ga-Pentixafor PET-CT in the classification diagnosis of primary aldosteronism concurrent with autonomous cortisol secretion patient, using AVS and/or postoperative remission as the reference standard for classification diagnosis.

Detailed description

This study is a multicenter, prospective, diagnostic trial involving patients with primary aldosteronism (PA) concurrent with autonomous cortisol secretion (ACS) patients with adrenal nodule (≥1cm) who completed both AVS and 68Ga-Pentixafor PET/CT. We will enroll 97 PA concurrent with ACS patients with adrenal nodule (≥1cm) .The treatment plan was determined according to the AVS results. AVS and/or postoperative remission were used as the reference standard for classification diagnosis to evaluate the accuracy of 68Ga-Pentixafor PET-CT in the classification diagnosis of PA concurrent with ACS patients.

Interventions

DIAGNOSTIC_TEST68Ga-Pentixafor PET/CT

The patients had a normal diet with no special preparation before 68Ga-Pentixafor PET/CT imaging. The dosage of intravenously injected 68Ga-Pentixafor was calculated based on the patient's weight (1.85 MBq \[0.05mCi\]/kg). Local PET/CT scanning of the upper abdomen was performed on a hybrid PET/CT scanner at 10 minutes after the injection of the intravenous tracer, respectively.

Sponsors

The First Affiliated Hospital of Zhengzhou University
CollaboratorOTHER
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
CollaboratorOTHER
The Third Xiangya Hospital of Central South University
CollaboratorOTHER
The Affiliated Hospital Of Southwest Medical University
CollaboratorOTHER
Qifu Li
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

1. Getting the written informed consent 2. The clear diagnosis of primary aldosteronism; 3. Combined with autonomous cortisol secretion, cortisol after 1mg dexamethasone suppression test (DST) ≥50 nmol/l; 4. Patients who are willing to undergo surgery; 5. Adrenal CT or MRI scan of the adrenal glands with nodule (≥1cm).

Exclusion criteria

1. PA patients who meet the by-passing AVS criteria \[i.e., younger than 35 years old, spontaneous hypokalemia, adrenal CT indicated unilateral low-density adenoma (≥1cm), plasma aldosterone &gt;300pg/ml\]; 2. Suspicion of familial hyperaldosteronism or Liddle syndrome. \[i.e., age &lt;20 years, hypertension and hypokalemia, or with family history\]; 3. Suspicion of pheochromocytoma or adrenal carcinoma; 4. Patients with actively malignant tumor; 5. Patients who have adrenalectomy history; 6. Long-term use of glucocorticoids; 7. Patients who are allergic to contrast media and cannot tolerate AVS; 8. Pregnant or lactating women; with alcohol or drug abuse and mental disorders; 9. Congestive heart failure with New York Heart Association (NYHA) Functional Classification III or IV; History of serious cardiovascular or cerebrovascular disease (angina, myocardial infarction or stroke) in the past 3 months; Severe anemia (Hb<60g/L); Serious liver dysfunction or chronic kidney disease aspartate aminotransferase (AST) or alanine transaminase (ALT) ≥3 times the upper limit of normal, or estimated glomerular filtration rate (eGFR) <30 ml/min/1.73 m2); Systemic Inflammatory Response Syndrome (SIRS); Uncontrolled diabetes (FBG≥13.3 mmol/L); Obesity (BMI≥35 kg/m²); Untreated aneurysm; Other comorbidity potentially interfering with treatment; 10. Consider patients with bilateral cortisol hypersecretion such as PBMAH or PPNAD.

Design outcomes

Primary

MeasureTime frameDescription
the accuracy of 68Ga-Pentixafor PET-CT in the classification diagnosis of PA concurrent with ACS patient6 monthsTo evaluate the accuracy of 68Ga-Pentixafor PET-CT in the classification diagnosis of primary aldosteronism concurrent with autonomous cortisol secretion patient, using AVS and/or postoperative remission as the reference standard for classification diagnosis.

Countries

China

Contacts

Primary ContactQi fu Li, PhD
liqifu@yeah.net86-89011552

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026